Mostrar el registro sencillo del ítem
A method to quantify several tyrosine kinase inhibitors in plasma by micellar liquid chromatography and validation according to the european medicines agency guidelines
dc.contributor.author | Garrido Cano, Iris | |
dc.contributor.author | García García, Aurelio | |
dc.contributor.author | Vives-Peris, Vicente | |
dc.contributor.author | Ochoa Aranda, Enrique | |
dc.contributor.author | Esteve-Romero, Josep | |
dc.date.accessioned | 2016-03-16T12:54:46Z | |
dc.date.available | 2016-03-16T12:54:46Z | |
dc.date.issued | 2015-11 | |
dc.identifier.citation | GARRIDO-CANO, Iris, et al. A method to quantify several tyrosine kinase inhibitors in plasma by micellar liquid chromatography and validation according to the European Medicines Agency guidelines. Talanta, 2015, vol. 144, p. 1287-1295. | ca_CA |
dc.identifier.uri | http://hdl.handle.net/10234/154050 | |
dc.description.abstract | A procedure based on micellar liquid chromatography has been developed to monitor five tyrosine kinase inhibitors in plasma, prescribed against several kinds of cancer: erlotinib, imatinib, sunitinib, sorafenib and lapatinib. The sample was diluted in a micellar solution and directly injected, thus clean-up steps were not required. The analytes were resolved without interferences in <20 min using a C18 column and a mobile phase of 0.13 M SDS-4% 1-butanol, buffered at pH 3.5, running under isocratic mode at 1 mL/min. The detection was performed by UV–visible absorbance, using a wavelength program to maximize the signal-to-noise ratio. The method was validated following the guideline of the European Medicines Agency in terms of: selectivity, calibration range (0.05–5 μg/mol), linearity (r2>0.990), limit of detection (15–35 ng/mL), carry-over effect, accuracy (−10.4 to +11.0%), precision (<9.2%), matrix effect, robustness (<8.4%) and stability. The procedure is rapid, easy-to-handle, uses a low amount of toxic chemical provide reliable results. Finally, the method was successfully used to analyze the studied tyrosine kinase inhibitors in plasma from cancer patients. | ca_CA |
dc.format.extent | 8 p. | ca_CA |
dc.format.mimetype | application/pdf | ca_CA |
dc.language.iso | eng | ca_CA |
dc.language.iso | deu | ca_CA |
dc.publisher | Elsevier | ca_CA |
dc.relation.isPartOf | Talanta Volume 144, 1 November 2015 | ca_CA |
dc.rights | Copyright © 2015 Elsevier B.V. All rights reserved. | ca_CA |
dc.rights.uri | http://rightsstatements.org/vocab/InC/1.0/ | * |
dc.subject | Direct injection | ca_CA |
dc.subject | Micellar | ca_CA |
dc.subject | Plasma | ca_CA |
dc.subject | Tyrosine kinase inhibitors | ca_CA |
dc.subject | Validation | ca_CA |
dc.title | A method to quantify several tyrosine kinase inhibitors in plasma by micellar liquid chromatography and validation according to the european medicines agency guidelines | ca_CA |
dc.type | info:eu-repo/semantics/article | ca_CA |
dc.identifier.doi | http://dx.doi.org/10.1016/j.talanta.2015.07.078 | |
dc.rights.accessRights | info:eu-repo/semantics/restrictedAccess | ca_CA |
dc.relation.publisherVersion | http://www.sciencedirect.com/science/article/pii/S0039914015302046 | ca_CA |
dc.type.version | info:eu-repo/semantics/publishedVersion | ca_CA |
Ficheros en el ítem
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |
Este ítem aparece en la(s) siguiente(s) colección(ones)
-
QFA_Articles [826]
Articles de publicacions periòdiques